Lantern Pharma Announces Q4 & Full-Year 2024 Financial Results and Portfolio Updates
Lantern Pharma Inc., a clinical-stage biopharmaceutical company utilizing its proprietary RADR® AI and machine learning platform to revolutionize oncology drug discovery and development, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company also provided key updates on its AI-driven drug candidates, enhancements to the RADR® platform for precision oncology, and other operational advancements.
Lantern Pharma Announces Q4 & Full-Year 2024 Financial Results and Portfolio Updates